Publications by authors named "Shunichiro Ohta"
Article Synopsis
- - The study aimed to assess care trends for patients with ANCA-associated vasculitis (AAV) over a decade, focusing on two specific types: granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).
- - Researchers compared patients treated in two different timeframes (early vs. late) and found that the late group used more rituximab (RTX) and required lower doses of glucocorticoids (GC), resulting in better remission rates and fewer complications.
- - The findings suggest that advancements in treatment strategies for AAV have led to improved patient outcomes, including effective disease management and reduced reliance on glucocorticoids over time.
Introduction: Progranulin (PGRN), a pleiotropic growth factor, has emerged as an immunoregulatory molecule. Because the roles of PGRN in dermatomyositis (DM) are still unknown, we investigated whether serum PGRN levels are associated with disease activity and prognosis in DM patients, particularly in those with DM complicated with interstitial lung disease (ILD).
Methods: The serum levels of PGRN were measured by enzyme-linked immunosorbent assay in patients with DM (n=57; acute/subacute interstitial pneumonia (A/SIP): n=17, chronic interstitial pneumonia (CIP): n=24, without ILD: n=16), polymyositis (PM, n=21; including 6 with ILD) and normal healthy controls (NHCs, n=60).
Background: Anti-tumor necrosis factor α (anti-TNF-α) agents have been successfully applied for the treatment of rheumatoid arthritis, Crohn's disease, and other chronic inflammatory diseases. Not only the neutralization of soluble TNF-α but also the effect on transmembrane TNF-α is important mechanisms of action of anti-TNF-α agents. This study investigated the cytotoxic effects of new anti-TNF-α agents, certolizumab pegol and golimumab, which are mediated by transmembrane TNF-α.
View Article and Find Full Text PDFIntroduction: Progranulin (PGRN) is the precursor of granulin (GRN), a soluble cofactor for toll-like receptor 9 (TLR9) signaling evoked by oligonucleotide (CpG)-DNA. Because TLR9 signaling plays an important role in systemic lupus erythematosus (SLE), we investigated whether PGRN is involved in the pathogenesis of SLE.
Methods: We measured concentrations of serum PGRN and interleukin-6 (IL-6) with enzyme-linked immunosorbent assay (ELISA) in patients with SLE (n = 68) and in healthy controls (n = 60).